Financial Results & KPIs

SHERIDAN, WYOMING - April 14, 2026 - SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) reported full-year 2025 financial results on March 19, 2026, disclosing $71.8 million in cash and cash equivalents as of December 31, 2025, and an additional $42.6 million in warrant exercise proceeds received in Q1 2026. The New York-based biopharmaceutical company advanced two lead oncology candidates simultaneously: galinpepimut-S (GPS), a WT1-targeting cancer immunotherapeutic in a pivotal Phase 3 trial for acute myeloid leukemia (AML), and SLS009 (tambiciclib), a selective CDK9 inhibitor now enrolling in a Phase 2 first-line AML study. The combined clinical and financial momentum positions SELLAS for multiple potential data readouts before year-end 2026.

SHERIDAN, WYOMING - April 14, 2026 - Mountain Province Diamonds Inc. (TSX/OTC: MPVD), a Canadian diamond producer holding a 49% interest in the Gahcho Kué mine in the Northwest Territories, announced on March 17, 2026 that it had entered into a third amending agreement to extend maturity on its credit facility and provided an update on cash call arrears. Two weeks later, on March 31, 2026, the company released its financial and operating results for the fourth quarter and full year 2025. Mountain Province operates within a joint venture alongside majority partner and operator De Beers, but markets and sells its share of rough diamond production independently - a structure the company characterizes as unique within the diamond industry.

SHERIDAN, WYOMING - April 14, 2026 - Sword Group, the IT and digital transformation provider, has disclosed full-year 2025 revenue of €357.7m, reflecting the operational scale it has built as a multinational technology services group. The firm employs more than 3,600 people and serves over 1,000 customers across 50 countries, operating an integrated portfolio that spans managed services, data and AI, cloud and security platforms, digital workplace transformation, and proprietary business application software. Sword Group positions its offering around measurable client outcomes - cost reduction, quality improvement, and productivity gain - aimed at enterprise and public-sector buyers evaluating multi-year IT partnerships.

SHERIDAN, WYOMING - April 14, 2026 - SCOR SE, one of the world's largest reinsurance groups, reported net income of EUR 208 million for the fourth quarter of 2025, a figure announced on March 4, 2026. The Paris-listed reinsurer followed the results disclosure with a series of regulatory and strategic publications - including the 2025 Universal Registration Document and the 2024 Activity Report - as it moves toward its 2026 Combined Shareholders' Meeting. Operating across Property & Casualty, Life & Health, and Investments segments, the group's disclosure sequence gives institutional investors, cedents, and rating agencies an updated view of financial performance and governance ahead of mid-year treaty negotiations.

SHERIDAN, WYOMING - April 14, 2026 - Apollo Commercial Real Estate Finance, Inc. (ARI), a publicly listed real estate investment trust externally managed by an Apollo Global Management subsidiary, reported a diversified loan portfolio with an amortized cost of $8.8 billion as of December 31, 2025, while simultaneously releasing its 2025 annual report (10-K) and Q4 earnings materials. The New York-based REIT focuses exclusively on senior mortgages, mezzanine loans, and related commercial real estate debt instruments secured by properties across the United States and Europe. The dual release of audited financials and quarterly results gives institutional investors, lenders, and borrowers a current picture of the platform's book entering 2026.

SHERIDAN, WYOMING - April 14, 2026 - Canadian General Investments, Limited (CGI), a closed-end investment fund established in 1930 and managed by Morgan Meighen & Associates since 1956, has published current portfolio metrics showing a net asset value per share of $85.16, a 2.3% yield, and a share price of $48.00 as of April 10, 2026. The fund filed its Annual Disclosure Documents on March 19, 2026, and followed with an unaudited investment update on April 6, 2026. With nearly a century of operating history, CGI continues to function as a long-duration vehicle providing investors with diversified exposure primarily to Canadian equity markets.

SHERIDAN, WYOMING - April 14, 2026 - Solventum Corporation, the healthcare technology and medical products company spun out from 3M with over 70 years of healthcare innovation behind it, has issued its 2025 Year-End Shareholder Letter and reported full-year financial results that reflect $8.3 billion in 2024 sales and a workforce exceeding 20,000 professionals. The company's Q4 2025 earnings, released April 14, 2026, were accompanied by full-year guidance for 2026, signaling a deliberate push to establish Solventum as an independent, growth-oriented healthcare enterprise. The shareholder letter and earnings release collectively define a company in active transformation, managing a broad portfolio spanning medical devices, oral care, health IT, and purification and filtration technologies.

SHERIDAN, WYOMING - April 13, 2026 - EQB Inc. (TSX: EQB), the parent of Equitable Bank - Canada's seventh largest bank by assets - reported adjusted diluted earnings per share of $2.26 for Q1 2026, a 48% sequential quarterly increase, while simultaneously receiving Competition Bureau clearance for its acquisition of PC Financial and appointing Daniel Rethazy as Executive Vice President of Personal Banking. The three developments, each materializing within weeks of each other in early 2026, mark a pivotal period for the digital challenger bank as it expands its customer base, broadens its product lines, and absorbs a major retail banking brand. With $142 billion in combined assets under management and administration as of April 13, 2026, EQB is executing a simultaneous growth and integration agenda that carries distinct implications for Canadian retail and commercial banking.

SHERIDAN, WYOMING - April 13, 2026 - Umicore reported full-year 2025 results showing adjusted EBITDA of €847 million, a 24.0% margin, and adjusted EBIT of €579 million - a 21% year-on-year increase - as its CORE strategy, launched in March 2025, drove measurable earnings recovery across foundation businesses including Catalysis, Recycling, and Specialty Materials. Group revenues reached €3.6 billion, up 3% versus 2024, while free operating cash flow hit €524 million and net debt closed the year at €1.4 billion, representing a 1.60x LTM EBITDA ratio. The results confirm that capital discipline and structural cost measures more than offset foreign exchange headwinds and inflation pressure. Battery Cathode Materials reached adjusted EBITDA break-even, a meaningful recovery milestone in a segment still navigating EV industry slowdown.

SHERIDAN, WYOMING - December 10, 2025 - Pfizer Inc. is setting the stage for its next financial chapter with an analyst conference call and webcast on December 16, 2025, where the U.S.-based biopharmaceutical leader will present full-year 2026 financial guidance to investors and the broader market. The event underscores how large pharma companies use structured guidance cycles to frame expectations around revenue, R&D investment, pipeline execution and capital allocation.

Anchoring Investor Expectations with 2026 Guidance

Pfizer will host the live call with investment analysts at 8:00 a.m. EST on Tuesday, December 16, 2025, with a simultaneous webcast for global stakeholders. The primary objective is to provide formal full-year 2026 financial guidance, giving clarity on topline trends, margin expectations, R&D spending and the company's capital deployment priorities.